|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Montgomery EA: Oesophageal cancer. World
Cancer Report 2014. Stewart BW and Wild CP: World Health
Organization, International Agency for Research on Cancer; Lyon:
pp. 528–543. 2014
|
|
3
|
Thrift AP: Global burden and epidemiology
of Barrett oesophagus and oesophageal cancer. Nat Rev Gastroenterol
Hepatol. 18:432–443. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sheikh M, Poustchi H, Pourshams A, Etemadi
A, Islami F, Khoshnia M, Gharavi A, Hashemian M, Roshandel G,
Khademi H, et al: Individual and combined effects of environmental
risk factors for esophageal cancer based on results from the
golestan cohort study. Gastroenterology. 156:1416–1427. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Watanabe M, Otake R, Kozuki R, Toihata T,
Takahashi K, Okamura A and Imamura Y: Recent progress in
multidisciplinary treatment for patients with esophageal cancer.
Surg Today. 50:12–20. 2020. View Article : Google Scholar :
|
|
6
|
Subramanian A, Narayan R, Corsello SM,
Peck DD, Natoli TE, Lu X, Gould J, Davis JF, Tubelli AA, Asiedu JK,
et al: A next generation connectivity map: L1000 platform and the
first 1000000 profiles. Cell. 171:1437–1452. 2017. View Article : Google Scholar
|
|
7
|
Ganci F, Pulito C, Valsoni S, Sacconi A,
Turco C, Vahabi M, Manciocco V, Mazza EMC, Meens J, Karamboulas C,
et al: PI3K inhibitors curtail myc-dependent mutant p53
gain-of-function in head and neck squamous cell carcinoma. Clin
Cancer Res. 26:2956–2971. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Aissa AF, Islam A, Ariss MM, Go CC, Rader
AE, Conrardy RD, Gajda AM, Rubio-Perez C, Valyi-Nagy K, Pasquinelli
M, et al: Single-cell transcriptional changes associated with drug
tolerance and response to combination therapies in cancer. Nature
Commun. 12:16282021. View Article : Google Scholar
|
|
9
|
Stathias V, Jermakowicz AM, Maloof ME,
Forlin M, Walters W, Suter RK, Durante MA, Williams SL, Harbour JW,
Volmar CH, et al: Drug and disease signature integration identifies
synergistic combinations in glioblastoma. Nat Commun. 9:53152018.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lin K, Li L, Dai Y, Wang H, Teng S, Bao X,
Lu ZJ and Wang D: A comprehensive evaluation of connectivity
methods for L1000 data. Brief Bioinform. 21:2194–2205. 2020.
View Article : Google Scholar
|
|
11
|
Zhang SD and Gant TW: A simple and robust
method for connecting small-molecule drugs using gene-expression
signatures. BMC Bioinformatics. 9:2582008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Oeckinghaus A and Ghosh S: The NF-kappaB
family of transcription factors and its regulation. Cold Spring
Harb Perspect Biol. 1:a0000342009. View Article : Google Scholar
|
|
13
|
Yu H, Lin L, Zhang Z, Zhang H and Hu H:
Targeting NF-kappaB pathway for the therapy of diseases: Mechanism
and clinical study. Signal Transduct Target Ther. 5:2092020.
View Article : Google Scholar
|
|
14
|
Tian F, Fan T, Zhang Y, Jiang Y and Zhang
X: Curcumin potentiates the antitumor effects of 5-FU in treatment
of esophageal squamous carcinoma cells through downregulating the
activation of NF-κB signaling pathway in vitro and in vivo. Acta
Biochim Biophys Sin (Shanghai). 44:847–855. 2012. View Article : Google Scholar
|
|
15
|
Tao J, Zhao H, Xie X, Luo M, Gao Z, Sun H
and Huang Z: The anthelmintic drug flubendazole induces cell
apoptosis and inhibits NF-kappaB signaling in esophageal squamous
cell carcinoma. Onco Targets Ther. 12:471–478. 2019. View Article : Google Scholar :
|
|
16
|
Taniguchi K and Karin M: NF-κB,
inflammation, immunity and cancer: Coming of age. Nat Rev Immunol.
18:309–324. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Podolin PL, Callahan JF, Bolognese BJ, Li
YH, Carlson K, Davis TG, Mellor GW, Evans C and Roshak AK:
Attenuation of murine collagen-induced arthritis by a novel,
potent, selective small molecule inhibitor of IkappaB kinase 2,
TPCA-1
(2-[(aminocarbonyl)amino]-5-(4-fluorophenyl)-3-thiophenecarboxamide),
occurs via reduction of proinflammatory cytokines and
antigen-induced T cell proliferation. J Pharmacol Exp Ther.
312:373–381. 2005. View Article : Google Scholar
|
|
18
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: Limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Patro R, Duggal G, Love MI, Irizarry RA
and Kingsford C: Salmon provides fast and bias-aware quantification
of transcript expression. Nat Methods. 14:417–419. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Soneson C, Love MI and Robinson MD:
Differential analyses for RNA-seq: Transcript-level estimates
improve gene-level inferences. F1000Res. 4:15212015. View Article : Google Scholar
|
|
21
|
Love MI, Huber W and Anders S: Moderated
estimation of fold change and dispersion for RNA-seq data with
DESeq2. Genome Biol. 15:5502014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yu G, Wang LG, Han Y and He QY:
clusterProfiler: An R package for comparing biological themes among
gene clusters. OMICS. 16:284–287. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Barret Schloerke DC, Joseph Larmarange,
Briatte Francois, Marbach Moritz, Thoen Edwin, Amos Elberg and
Crowley Jason: GGally: Extension to 'ggplot2'. R package version
2.0.0. https://CRAN.R-project.org/package=GGally.
|
|
24
|
Duan Y, Evans DS, Miller RA, Schork NJ,
Cummings SR and Girke T: signatureSearch: Environment for gene
expression signature searching and functional interpretation.
Nucleic Acids Res. 48:e1242020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kolde R, Laur S, Adler P and Vilo J:
Robust rank aggregation for gene list integration and
meta-analysis. Bioinformatics. 28:573–580. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Spector AA: Arachidonic acid cytochrome
P450 epoxygenase pathway. J Lipid Res. 50(Suppl): S52–S56. 2009.
View Article : Google Scholar :
|
|
27
|
Khasawneh J, Schulz MD, Walch A, Rozman J,
de Angelis M, Klingenspor M, Buck A, Schwaiger M, Saur D, Schmid
RM, et al: Inflammation and mitochondrial fatty acid beta-oxidation
link obesity to early tumor promotion. Proc Natl Acad Sci USA.
106:3354–3359. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Keenan AB, Jenkins SL, Jagodnik KM, Koplev
S, He E, Torre D, Wang Z, Dohlman AB, Silverstein MC, Lachmann A,
et al: The library of integrated network-based cellular signatures
NIH program: System-level cataloging of human cells response to
perturbations. Cell Syst. 6:13–24. 2018. View Article : Google Scholar
|
|
29
|
Ghandi M, Huang FW, Jane-Valbuena J,
Kryukov GV, Lo CC, McDonald ER III, Barretina J, Gelfand ET,
Bielski CM, Li H, et al: Next-generation characterization of the
cancer cell line encyclopedia. Nature. 569:503–508. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Seth R, Messersmith H, Kaur V, Kirkwood
JM, Kudchadkar R, McQuade JL, Provenzano A, Swami U, Weber J,
Alluri KC, et al: Systemic therapy for melanoma: ASCO guideline. J
Clin Oncol. 38:3947–3970. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Argnani L, Broccoli A and Zinzani PL:
Cutaneous T-cell lymphomas: Focusing on novel agents in relapsed
and refractory disease. Cancer Treat Rev. 61:61–69. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ciancio G, Burke GW, Gaynor JJ, Mattiazzi
A, Roth D, Kupin W, Nicolas M, Ruiz P, Rosen A and Miller J: A
randomized long-term trial of tacrolimus and sirolimus versus
tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL)
and sirolimus in renal transplantation. I. Drug interactions and
rejection at one year. Transplantation. 77:244–251. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cheng L and Li L: Systematic quality
control analysis of LINCS data. CPT Pharmacometrics Syst Pharmacol.
5:588–598. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bollag G, Hirth P, Tsai J, Zhang J,
Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, et al:
Clinical efficacy of a RAF inhibitor needs broad target blockade in
BRAF-mutant melanoma. Nature. 467:596–599. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Markham A and Keam SJ: Selumetinib: First
approval. Drugs. 80:931–937. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bensen W, Weaver A, Espinoza L, Zhao WW,
Riley W, Paperiello B and Recker DP: Efficacy and safety of
valdecoxib in treating the signs and symptoms of rheumatoid
arthritis: A randomized, controlled comparison with placebo and
naproxen. Rheumatology (Oxford). 41:1008–1016. 2002. View Article : Google Scholar
|
|
37
|
Liu Y, Wang X, Zeng S, Zhang X, Zhao J,
Zhang X, Chen X, Yang W, Yang Y, Dong Z, et al: The natural
polyphenol curcumin induces apoptosis by suppressing STAT3
signaling in esophageal squamous cell carcinoma. J Exp Clin Cancer
Res. 37:3032018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tung LN, Song S, Chan KT, Choi MY, Lam HY,
Chan CM, Chen Z, Wang HK, Leung HT, Law S, et al: Preclinical study
of novel curcumin analogue SSC-5 using orthotopic tumor xenograft
model for esophageal squamous cell carcinoma. Cancer Res Treat.
50:1362–1377. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Liu W, Xie L, He YH, Wu ZY, Liu LX, Bai
XF, Deng DX, Xu XE, Liao LD, Lin W, et al: Large-scale and
high-resolution mass spectrometry-based proteomics profiling
defines molecular subtypes of esophageal cancer for therapeutic
targeting. Nat Commun. 12:49612021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li B, Li YY, Tsao SW and Cheung AL:
Targeting NF-kappaB signaling pathway suppresses tumor growth,
angiogenesis, and metastasis of human esophageal cancer. Mol Cancer
Ther. 8:2635–2644. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Boehm JS and Golub TR: An ecosystem of
cancer cell line factories to support a cancer dependency map. Nat
Rev Genet. 16:373–374. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Papageorgis P, Cheng K, Ozturk S, Gong Y,
Lambert AW, Abdolmaleky HM, Zhou JR and Thiagalingam S: Smad4
inactivation promotes malignancy and drug resistance of colon
cancer. Cancer Res. 71:998–1008. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen YW, Hsiao PJ, Weng CC, Kuo KK, Kuo
TL, Wu DC, Hung WC and Cheng KH: SMAD4 loss triggers the phenotypic
changes of pancreatic ductal adenocarcinoma cells. BMC Cancer.
14:1812014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ozawa H, Ranaweera RS, Izumchenko E,
Makarev E, Zhavoronkov A, Fertig EJ, Howard JD, Markovic A, Bedi A,
Ravi R, et al: SMAD4 loss is associated with cetuximab resistance
and induction of MAPK/JNK activation in head and neck cancer cells.
Clin Cancer Res. 23:5162–5175. 2017. View Article : Google Scholar : PubMed/NCBI
|
